- 12/10/2020
- BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPAN
- 11/30/2020
- EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
- 11/30/2020
- EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIES
- 11/27/2020
- AbbVie and Eisai Announce an approval for additional indication of HUMIRA®, a fully Human Anti-TNFα Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world
- 11/26/2020
- EISAI COMMENCES “PaDiCo” SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSON’S DISEASE
- 11/18/2020
- JYSELECA® (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPAN
- 11/18/2020
- EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME
- 11/10/2020
- LENVIMA® Plus KEYTRUDA® Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
- 11/09/2020
- Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
- 10/30/2020
- European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer’s Disease
